Nova selects new chairman of board

October 15, 1991|By Timothy J. Mullaney

Nova Pharmaceutical Corp. has tapped a retired executive from one of the nation's biggest drug companies to be its new chairman of the board, the Baltimore-based drug research and development company said yesterday.

Donald E. O'Neill, 65, who retired earlier this year as executive vice president and chairman of international operations at Warner-Lambert Co. in Morris Plains, N.J., will succeed John Lloyd Huck as chairman of the board. Mr. Huck, 68, is retiring as chairman but will remain on the board.

Mr. O'Neill, who lives in Florida, will not have an operating role, said Hans Mueller, Nova's president and chief executive officer, who runs the company's day-to-day affairs.

"It's clearly the role of an adviser, someone who can make connections in the industry," he said.

Dr. Mueller said that Nova has a history of having a chairman who doesn't serve as CEO and who has experience as a senior executive at a major drug company. Mr. Huck, who has been chairman since 1986, is a former Merck & Co. executive.

Mr. O'Neill has served as president of Warner-Lambert's Parke-Davis Group, which makes prescription drugs. He has also headed the Parke-Davis research division.

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.